Inactive Instrument

Other languages Diffusion Pharma

Equities

DFFN

US2537484048

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

EIP Pharma, Inc. completed the acquisition of Diffusion Pharmaceuticals Inc. in a reverse merger transaction.	23-08-15
Diffusion Pharmaceuticals Shareholders Approve Merger With EIP Pharma; Shares Rise	23-08-15
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Diffusion Pharmaceuticals Inc. Appoints Jill Davidson as A Director of the Company, Effective July 26, 2023	23-07-31
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Top Premarket Gainers	23-04-17
Diffusion Pharmaceuticals, EIP Pharma Agree to Merge to Create New Combined Entity	23-03-30
Diffusion Pharmaceuticals Inc. Announces Resignation of Christopher D. Galloway as Chief Medical Officer, Effective March 1, 2023	23-02-16
Diffusion Pharmaceuticals Inc Sends a Letter to Shareholders	22-12-05
Diffusion Pharmaceuticals Inc Send a Letter to Shareholders	22-11-28
LifeSci Special Opportunities Master Fund Ltd Issues an Open Letter to Shareholders of Diffusion Pharmaceuticals Inc	22-11-18
LS Capital, Inc., on behalf of a client and unaffiliated investor in Diffusion Pharmaceuticals Inc. cancelled the acquisition of remaining shares of Diffusion Pharmaceuticals Inc..	22-11-16
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Diffusion Pharmaceuticals Inc. Announces Resignation of Eric Francois from the Board of Directors and All Committees and Subcommittees	22-11-14
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives Including Opportunities to Better	22-10-25
Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11
Diffusion to Launch Phase 2 Trial of Trans Sodium Crocetinate in Brain Cancer By Year End	22-07-26
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation	22-07-26
Diffusion Pharmaceuticals Reports Positive Effects of TSC in Second Oxygenation Trial	22-06-23
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial	22-06-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Diffusion Pharma

Equities

DFFN

US2537484048

Other languages

Filters